SCH-58500

N/A

Report date: 2024/01/19 15:04:12

Base Information

Drug NameSCH-58500
Drug Alias NamerAd/p53 - Schering-Ploughp53 gene therapy - Schering-PloughraDP-53 SCH 58500SCH-58500
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adenoviral vector
Mechanisms of ActionGene transferenceTumor protein p53 stimulants
TargetsTumor protein p53
Therapy Area/IndicationsUrinary Bladder NeoplasmsFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesSchering - Plough SaOre Pharmaceuticals IncMerck & Co Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesOre Pharmaceuticals IncMerck Sharp & Dohme CorpSchering - Plough Sa
Active IndicationsN/A
Inactive IndicationsUrinary Bladder NeoplasmsFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[7] 

Other Information

ATC CodeN/A
Related LinksN/A